Vascular biology in uremia: Insights into novel mechanisms of vascular injury

Advances in Chronic Kidney Disease

Volumn 11, Issue 3, 2004, Pages 310-318

  Al Aly, Ziyad ^a   Edwards, John C ^a,b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

asymmetric dimethylarginine; cardiovascular disease; endothelial dysfunction; Inflammation; myeloperoxidase; vascular calcification

Indexed keywords

ARGININE; DIMETHYLARGININE; IBANDRONIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPEROXIDASE; OSTEOCALCIN; OSTEOPROTEGERIN; PHOSPHORUS; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY; EMBRYO DEVELOPMENT; ENCHONDRAL OSSIFICATION; ENDOTHELIUM INJURY; HUMAN; INFECTION; KIDNEY FAILURE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; UREMIA;

EID: 3242661846     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2004.04.006     Document Type: Article

References (86)

1. USRDS the United States Renal Data System. Am J Kidney Dis. 42:(suppl 5):2003;1-230
2. Shoji T., Emoto M., Tabata T., et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 61:2002;2187-2192
3. Ishimura E., Shoji T., Emoto M., et al. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 38:(suppl 1):2001;S186-S190
4. Kimmel P.L., Phillips T.M., Simmens S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54:1998;236-244
5. Pecoits-Filho R., Barany P., Lindholm B., et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 17:2002;1684-1688
6. Yeun J.Y., Levine R.A., Mantadilok V., et al. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 35:2000;469-476
7. Yudkin J.S., Kumari M., Humphries S.E., et al. Inflammation, obesity, stress and coronary heart disease Is interleukin-6 the link? Atherosclerosis. 148:2000;209-214
8. Huber S.A., Sakkinen P., Conze D., et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 19:1999;2364-2367
9. Pigott R., Dillon L.P., Hemingway I.H., et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 187:1992;584-589
10. Wassmann S., Stumpf M., Strehlow K., et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 94:2004;534-541
11. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772
12. Kato A., Odamaki M., Takita T., et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 61:2002;1143-1152
13. Stenvinkel P., Barany P., Heimburger O., et al. Mortality, malnutrition, and atherosclerosis in ESRD What is the role of interleukin-6? Kidney Int. 80:(suppl):2002;103-108
14. Stenvinkel P., Heimburger O., Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 39:2002;274-282
15. Netea M.G., Selzman C.H., Kullberg B.J., et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 30:2000;541-549
16. Tsirpanlis G., Chatzipanagiotou S., Ioannidis A., et al. The effect of viable Chlamydia pneumoniae on serum cytokines and adhesion molecules in hemodialysis patients. Kidney Int. 84:(suppl):2003;S72-S75
17. Zoccali C., Mallamaci F., Tripepi G., et al. Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney Int. 64:2003;579-584
18. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 85:1999;E17-E24
19. Von Der Thusen J.H., Kuiper J., Fekkes M.L., et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. 15:2001;2730-2732
20. Perianayagam M.C., Jaber B.L., Guo D., et al. Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif. 20:2002;543-550
21. Girndt M., Kaul H., Sester U., et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 62:2002;949-955
22. Annuk M., Zilmer M., Lind L., et al. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 12:2001;2747-2752
23. Fillit H., Elion E., Sullivan J., et al. Thiobarbituric acid reactive material in uremic blood. Nephron. 29:1981;40-43
24. Taccone-Gallucci M., Lubrano R., Del Principe D., et al. Platelet lipid peroxidation in haemodialysis patients Effects of vitamin E supplementation. Nephrol Dial Transplant. 4:1989;975-978
25. Annuk M., Fellstrom B., Akerblom O., et al. Oxidative stress markers in pre-uremic patients. Clin Nephrol. 56:2001;308-314
26. Holvoet P., Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 137:(suppl):1998;S33-38
27. Dawnay A., Millar D.J. The pathogenesis and consequences of AGE formation in uraemia and its treatment. Cell Mol Biol (Noisy-le-grand). 44:1998;1081-1094
28. Nguyen-Khoa T., Massy Z.A., De Bandt J.P., et al. Oxidative stress and haemodialysis Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant. 16:2001;335-340
29. Wang H.H., Hung T.M., Wei J., et al. Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res. 61:2004;169-176
30. Fleck C., Schweitzer F., Karge E., et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 336:2003;1-12
31. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 20:2000;2032-2037
32. Zoccali C., Mallamaci F., Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 15:(suppl 1):2004;S77-S80
33. Boger R.H., Zoccali C. ADMA A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler. 4:(suppl):2003;23-28
34. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62:2002;339-345
35. Zoccali C., Benedetto F.A., Maas R., et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 13:2002;490-496
36. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease A prospective study. Lancet. 358:2001;2113-2117
37. Podrez E.A., Abu-Soud H.M., Hazen S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 28:2000;1717-1725
38. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 99:1997;2075-2081
39. Podrez E.A., Schmitt D., Hoff H.F., et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 103:1999;1547-1560
40. Schmitt D., Shen Z., Zhang R., et al. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry. 38:1999;16904-16915
41. Zhang R., Brennan M.L., Shen Z., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 277:2002;46116-46122
42. Abu-Soud H.M., Hazen S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 275:2000;37524-37532
43. Himmelfarb J., McMenamin M.E., Loseto G., et al. Myeloperoxidase- catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 31:2001;1163-1169
44. Kutter D., Devaquet P., Vanderstocken G., et al. Consequences of total and subtotal myeloperoxidase deficiency Risk or benefit? Acta Haematol. 104:2000;10-15
45. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2001;2136-2142
46. Pecoits-Filho R., Stenvinkel P., Marchlewska A., et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. 84:(suppl):2003;S172-S176
47. Nikpoor B., Turecki G., Fournier C., et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 142:2001;336-339
48. Annuk M., Zilmer M., Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure impact on cardiovascular disease. Kidney Int. 84:(suppl):2003;S50-S53
49. Bolto C.H., Downs L.G., Victory J.G., et al. Endothelial dysfunction in chronic renal failure roles of lipoprotein oxidation and proinflammatory cytokines. Nephrol Dial Transplant. 16:2001;1189-1197
50. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 342:2000;1478-1483
51. Salgueira M., Del Toro N., Moreno-Alba R., et al. Vascular calcification in the uremic patient A cardiovascular risk? Kidney Int. 85:(suppl):2003;119-121
52. Reslerova M., Moe S.M. Vascular calcification in dialysis patients Pathogenesis and consequences. Am J Kidney Dis. 41:(suppl 1):2003;S96-S99
53. Blacher J., Guerin A.P., Pannier B., et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 38:2001;938-942
54. London G.M., Guerin A.P., Marchais S.J., et al. Arterial media calcification in end-stage renal disease Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 18:2003;1731-1740
55. Virchow R. Cellular Pathology As Based Upon Physiological and Pathological Histology. 1971;Dover, New York, NY
56. Tintut Y., Demer L.L. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol. 12:2001;555-560
57. Demer L.L., Tintut Y. Mineral exploration: Search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol. 23:2003;1739-1743
58. Towler D.A., Bidder M., Latifi T., et al. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 273:1998;30427-30434
59. Engelse M.A., Neele J.M., Bronckers A.L., et al. Vascular calcification Expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix Gla protein in human atherogenesis. Cardiovasc Res. 52:2001;281-289
60. Bostrom K., Watson K.E., Horn S., et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 91:1993;1800-1809
61. Parhami F., Bostrom K., Watson K., et al. Role of molecular regulation in vascular calcification. J Atheroscler Thromb. 3:1996;90-94
62. Giachelli C.M. Ectopic calcification gathering hard facts about soft tissue mineralization. Am J Pathol. 154:1999;671-675
63. Luo G., Ducy P., McKee M.D., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 386:1997;78-81
64. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390:1997;45-51
65. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1998;1260-1268
66. Tintut Y., Patel J., Parhami F., et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 102:2000;2636-2642
67. Tintut Y., Patel J., Territo M., et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 105:2002;650-655
68. Ketteler M., Vermeer C., Wanner C., et al. Novel insights into uremic vascular calcification Role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood Purif. 20:2002;473-476
69. Price P.A., Williamson M.K. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem. 260:1985;14971-14975
70. Price P.A., Faus S.A., Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 20:2000;317-327
71. Farzaneh-Far A., Davies J.D., Braam L.A., et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem. 276:2001;32466-32473
72. Herrmann S.M., Whatling C., Brand E., et al. Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 20:2000;2386-2393
73. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis A cross-sectional study. Lancet. 361:2003;827-833
74. Ketteler M., Wanner C., Metzger T., et al. Deficiencies of calcium-regulatory proteins in dialysis patients A novel concept of cardiovascular calcification in uremia. Kidney Int. 84:(suppl):2003;S84-S87
75. Schafer C., Heiss A., Schwarz A., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 112:2003;357-366
76. Lebreton J.P., Joisel F., Raoult J.P., et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 64:1979;1118-1129
77. Binkert C., Demetriou M., Sukhu B., et al. Regulation of osteogenesis by fetuin. J Biol Chem. 274:1999;28514-28520
78. Mathews S.T., Singh G.P., Ranalletta M., et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 51:2002;2450-2458
79. Jahnen-Dechent W., Schinke T., Trindl A., et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem. 272:1997;31496-31503
80. Price P.A., Williamson M.K., Nguyen T.M., et al. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 279:2004;1594-1600
81. Proudfoot D., Skepper J.N., Shanahan C.M., et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 18:1998;379-388
82. Canfield A.E., Farrington C., Dziobon M.D., et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis An immunohistochemical study. J Pathol. 196:2002;228-234
83. Jono S., McKee M.D., Murry C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 87:2000;E10-E17
84. Giachelli C.M., Jono S., Shioi A., et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis. 38:(suppl 1):2001;S34-S37
85. Wolf G., Chen S., Han D.C., et al. Leptin and renal disease. Am J Kidney Dis. 39:2002;1-11
86. Parhami F., Tintut Y., Ballard A., et al. Leptin enhances the calcification of vascular cells Artery wall as a target of leptin. Circ Res. 88:2001;954-960